Glybera is a treatment for patients who cannot produce enough of an enzyme that is crucial for breaking down fat. Glybera uses a virus that is injected into the patient to deliver a working copy of a gene for producing lipoprotein lipase (LPL). LPL deficiency is very rare, affecting no more than one or two people in every million.
Learn more about the first european approval for a gene therapy
25 Jul 2012
1st european appoval for a gene therapy drug
